[165 Pages Report]The global regenerative medicine market is expected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9%. Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products.

To know about the assumptions considered for the study, Request for Free Sample Report

OVID-19 Impact on Global Regenerative medicine market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. This pandemic has disrupted growth in many economies across various domains. The COVID-19 outbreak will impact the regenerative medicine market in the initial phase of the forecast period. Due to nationwide lockdowns, denied wound care services, cancelled or postponed elective surgeries, and increasing skin injuries in COVID-19 medical care providers, the regenerative medicine market is expected to register a certain decline during the forecast period. However, during the latter half of the forecast period, the demand for regenerative medicine products is expected to rise drastically.

Market Dynamics

Driver: Growing prevalence of chronic diseases, genetic disorders, and cancer

Over the last few decades, the incidence and prevalence of chronic diseases such as CVD, cancer, diabetes, ulcers, and genetic disorders such as cystic fibrosis have increased significantly across the globe. Diabetes and obesity can result in the increased incidence and complexity of wounds such as infections, ulcerations (leg or foot ulcers), and surgical wounds, which require treatments and incur exorbitant medical expenses.

Opportunity: Implementation of the 21st Century Cures Act

The 21st Century Cures Act was signed into law in the US in December 2016. Among other objectives, this new law has been enacted to advance regenerative medicine research and medical innovation and covers various provisions that may impact the development and approval of several products in the coming years.

Restraint: High cost cell and gene therapies

Cell and gene therapies represent a significant scientific and medical advancement for patients suffering from terminal illnesses and serious disorders. These therapies are helping to transform how diseases are treated and potentially cured. Furthermore, such therapies will eventually enable doctors and medical professionals to infuse genes/cells via injectable means in order to avoid a series of drugs and multiple surgeries in patients. However, despite the fact of these therapies being lifesavers and more effective compared to the traditional treatments, the response in terms of demand for these therapies is less compared to the anticipation. This can be attributed to the high costs of these therapies and difficulty in obtaining reimbursements and coverage for these therapies.

Tissue-engineered products segment accounted for the largest share of the regenerative medicine market, by product, in 2019

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The tissue-engineered products segment accounted for the largest share in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Musculoskeletal segment accounted for largest share in the market, by application, in 2019

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the musculoskeletal disorders segment accounted for the largest market share. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

North America is the largest regional market for regenerative medicine market

The global regenerative medicine market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share in the regenerative medicine market. The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

To know about the assumptions considered for the study, download the pdf brochure

Some key players in the regenerative medicine market (2020- 2025)

Scope of the Report

Report Metric Details Market size available for years 2018�2025 Base year considered 2019 Forecast period 2020�2025 Forecast units Value (USD) Segments covered Product, application, and region Geographies covered North America, Europe, Asia Pacific, and Rest of the Wo Companies covered 3M (US), Allergan plc (Ireland), Amgen, Inc. (US), Aspect Biosystems (Canada), bluebird bio (US), Kite Pharma (US), Integra LifeSciences Holdings Corporation (US), MEDIPOST Co., Ltd. (South Korea), Medtronic plc (Ireland), Anterogen Co., Ltd. (South Korea), MiMedx Group (US), Misonix (US), Novartis AG (Switzerland), Organogenesis Inc. (US), Orthocell Limited (Australia), Corestem, Inc. (South Korea), Spark Therapeutics (US), APAC Biotech (India), Shenzhen Sibiono GeneTech Co., Ltd. (China), Smith & Nephew plc (UK), Stryker Corporation (US), Takeda Pharmaceutical Company Limited (Japan), Tego Science (South Korea), Vericel Corporation (US), and Zimmer Biomet (US).

This report categorizes the regenerative medicine market into the following segments and subsegments:

By Product

Tissue-engineered Products

Cell Therapies Autologous Therapies Allogenic Therapies

Gene Therapies

Progenitor & Stem Cell Therapies

By Application

Musculoskeletal

Oncology

Wound Care

Dental

Ocular

Other Applications

By Region

North America US Canada

Europe UK Germany France Rest of Europe

Asia Pacific Japan China Australia Rest of Asia Pacific

Rest of the World

Recent Developments

In February 2020, Integra Lifesciences (US) launched AmnioExcel Plus Placental allograft membrane.

In November 2019, Stryker Corporation (US) acquired Wright Medical (US) to strengthen its product portfolio.

In March 2019, Smith & Nephew (UK) acquired Osiris Therapeutics (US) to strengthen its product portfolio.

Frequently Asked Questions (FAQ):

What are the recent trends affecting the regenerative medicine market? Recent trends affecting the regenerative medicine market are: COVID-19 outbreak, ririsng skin diseases and wounds in doctos and nurse using PPE kits 2 and 3 for COVID-19 duty; increasing adotpion in emerging economies and rising geriatric population; and cancellations of elective surgeries across the globe. Who are the key players in the market, and how intense is the competition? The key players in this market are: 3M (US), Allergan plc (Ireland), Amgen, Inc. (US), Aspect Biosystems (Canada), bluebird bio (US), Kite Pharma (US), Integra LifeSciences Holdings Corporation (US), MEDIPOST Co., Ltd. (South Korea), Medtronic plc (Ireland), Anterogen Co., Ltd. (South Korea), MiMedx Group (US), Misonix (US), Novartis AG (Switzerland), Organogenesis Inc. (US), Orthocell Limited (Australia), Corestem, Inc. (South Korea), Spark Therapeutics (US), APAC Biotech (India), Shenzhen Sibiono GeneTech Co., Ltd. (China), Smith & Nephew plc (UK), Stryker Corporation (US), Takeda Pharmaceutical Company Limited (Japan), Tego Science (South Korea), Vericel Corporation (US), and Zimmer Biomet (US). What are the key applications of regenerative medicine products? These products are used in various applications like wound care, musculoskeletal disorders, dental disorders, dermatology, ocular diseases, gynaecology diseases amongst others. Which region is lucrative for the regenerative medicine market? The emerging economies in Asia Pacific region like China, Japan, Australia will be the lucrative markets for regenerative medicine products. .

To speak to our analyst for a discussion on the above findings, click Speak to Analyst